|Bid||142.00 x 900|
|Ask||143.32 x 2200|
|Day's Range||142.19 - 147.07|
|52 Week Range||73.32 - 167.33|
|Beta (5Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||163.85|
Alnylam (ALNY) posts a narrower-than-expected loss in the second quarter of 2020 and sales miss estimates.
Alnylam (ALNY) delivered earnings and revenue surprises of 12.85% and 5.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2020 and reviewed recent business highlights.